Search

This paper aims to demonstrate the technical feasibility of a historical study devoted to French nuclear power plants (NPPs) which can be prone to extreme coastal flooding events. It has been shown in the literature that the use of historical information (HI) can significantly improve the probabilistic and statistical modeling of extreme events. There is a significant lack of historical data on coastal flooding (storms and storm surges) compared to river flooding events. To address this data scarcity and to improve the estimation of the risk associated with coastal flooding hazards, a dataset of historical storms and storm surges that hit the Nord-Pas-de-Calais region during the past five centuries was created from archival sources, examined and used in a frequency analysis (FA) in order to assess its impact on frequency estimations. This work on the Dunkirk site (representative of the Gravelines NPP) is a continuation of previous work performed on the La Rochelle site in France. Indeed, the frequency model (FM) used in the present paper had some success in the field of coastal hazards and it has been applied in previous studies to surge datasets to prevent coastal flooding in the La Rochelle region in France.In a first step, only information collected from the literature (published reports, journal papers and PhD theses) is considered. Although this first historical dataset has extended the gauged record back in time to 1897, serious questions related to the exhaustiveness of the information and about the validity of the developed FM have remained unanswered. Additional qualitative and quantitative HI was extracted in a second step from many older archival sources. This work has led to the construction of storm and coastal flooding sheets summarizing key data on each identified event. The quality control and the cross-validation of the collected information, which have been carried out systematically, indicate that it is valid and complete in regard to extreme storms and storm surges. Most of the HI collected is in good agreement with other archival sources and documentary climate reconstructions. The probabilistic and statistical analysis of a dataset containing an exceptional observation considered as an outlier (i.e., the 1953 storm surge) is significantly improved when the additional HI collected in both literature and archives is used. As the historical data tend to be extreme, the right tail of the distribution has been reinforced and the 1953 exceptional event does not appear as an outlier any more. This new dataset provides a valuable source of information on storm surges for future characterization of coastal hazards.

Nuclear power plants located in the French Atlantic coast are designed to be protected against extreme environmental conditions. The French authorities remain cautious by adopting a strict policy of nuclear-plants flood prevention. Although coastal nuclear facilities in France are designed to very low probabilities of failure (e.g., 1000-year surge), exceptional surges (outliers induced by exceptional climatic events) have shown that the extreme sea levels estimated with the current statistical approaches could be underestimated. The estimation of extreme surges then requires the use of a statistical analysis approach having a more solid theoretical motivation. This paper deals with extreme-surge frequency estimation using historical information (HI) about events occurred before the systematic record period. It also contributes to addressing the problem of the presence of outliers in data sets. The frequency models presented in the present paper have been quite successful in the field of hydrometeorology and river flooding but they have not been applied to sea level data sets to prevent marine flooding. In this work, we suggest two methods of incorporating the HI: the peaks-over-threshold method with HI (POTH) and the block maxima method with HI (BMH). Two kinds of historical data can be used in the POTH method: classical historical maxima (HMax) data, and over-a-threshold supplementary (OTS) data. In both cases, the data are structured in historical periods and can be used only as complement to the main systematic data. On the other hand, in the BMH method, the basic hypothesis in statistical modeling of HI is that at least one threshold of perception exists for the whole period (historical and systematic) and that during a giving historical period preceding the period of tide gauging, only information about surges above this threshold have been recorded or archived. The two frequency models were applied to a case study from France, at the La Rochelle site where the storm Xynthia induced an outlier, to illustrate their potentials, to compare their performances and especially to analyze the impact of the use of HI on the extreme-surge frequency estimation.

In France, nuclear facilities were designed around very low probabilities of failure. Nevertheless, some extreme climatic events have given rise to exceptional observed surges (outliers) much larger than other observations, and have clearly illustrated the potential to underestimate the extreme water levels calculated with the current statistical methods. The objective of the present work is to conduct a comparative study of three approaches to extreme value analysis, including the annual maxima (AM), the peaks-over-threshold (POT) and the r-largest order statistics (r-LOS). These methods are illustrated in a real analysis case study. All data sets were screened for outliers. Non-parametric tests for randomness, homogeneity and stationarity of time series were used. The shape and scale parameter stability plots, the mean excess residual life plot and the stability of the standard errors of return levels were used to select optimal thresholds and r values for the POT and r-LOS method, respectively. The comparison of methods was based on (i) the uncertainty degrees, (ii) the adequacy criteria and tests, and (iii) the visual inspection. It was found that the r-LOS and POT methods have reduced the uncertainty on the distribution parameters and return level estimates and have systematically shown values of the 100 and 500-year return levels smaller than those estimated with the AM method. Results have also shown that none of the compared methods has allowed a good fit at the right tail of the distribution in the presence of outliers. As a perspective, the use of historical information was proposed in order to increase the representativeness of outliers in data sets. Findings are of practical relevance, not only to nuclear energy operators in France, for applications in storm surge hazard analysis and flood management, but also for the optimal planning and design of facilities to withstand extreme environmental conditions, with an appropriate level of risk.

A good knowledge of extreme storm surges is necessary to ensure protection against flood. In this paper we introduce a methodology to determine time series of skew surges in France as well as a statistical approach for estimating extreme storm surges. With the aim to cope with the outlier issue in surge series, a regional frequency analysis has been carried out for the surges along the Atlantic coast and the Channel coast. This methodology is not the current approach used to estimate extreme surges in France. First results showed that the extreme events identified as outliers in at-site analyses do not appear to be outliers any more in the regional empirical distribution. Indeed the regional distribution presents a curve to the top with these extreme events that a mixed exponential distribution seems to recreate. Thus, the regional approach appears to be more reliable for some sites than at-site analyses. A fast comparison at a given site showed surge estimates with the regional approach and a mixed exponential distribution are higher than surge estimates with an at-site fitting. In the case of Brest, the 1000-yr return surge is 167 cm in height with the regional approach instead of 126 cm with an at-site analysis.

Purpose: The COVID-19 vaccination campaign began in December 2020, in France, and primarily targeted the oldest people. Our study aimed to determine the level of acceptance of vaccination in a population of older patients with cancer., Methods: From January 2021, we offered vaccination with the BNT162b2 COVID-19 vaccine to all patients 70 years and older referred to our geriatric oncology center in Marseille University Hospital (AP-HM) for geriatric assessment before initiation of an oncological treatment. Objectives were to evaluate acceptance rate of COVID-19 vaccination and to assess vaccine safety, reactogenicity, and efficacy two months after the first dose., Results: Between January 18, 2021 and May 7, 2021, 150 older patients with cancer were offered vaccination after a geriatric assessment. The majority were men (61.3%), with a mean age of 81 years. The two most frequent primary tumors were digestive (29.4%) and thoracic (18%). The vaccine acceptance rate was 82.6% and the complete vaccination rate (2 doses) reached 75.3%. Among the vaccinated patients, 15.9% reported mild side effects after the first dose and 23.4% after the second dose, mostly arm pain and fatigue. COVID-19 cases were observed in 5.1% of vaccinated patients compared with 16.7% in unvaccinated patients. Of the 22 vaccinated patients who agreed to have their serum tested, 15 had antibodies against the spike protein at day 21 after the first dose., Conclusion: Our study showed a high acceptance rate of COVID-19 vaccination, with good tolerance in this frail population. These results highlight the benefits of organizing vaccination campaigns at the very beginning of oncological management in older patients., Clinical Trial Registration: This study was registered May 23, 2019 in ClinicalTrials.gov (NCT03960593)., (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting in an ultramutated genome and to sensitize tumors to checkpoint blockade immunotherapy. However, many POLE-mutated tumors do not respond to such treatment. To better understand the link between POLE mutation variants and response to immunotherapy, we prospectively assessed the efficacy of nivolumab in a multicenter clinical trial in patients bearing advanced mismatch repair-proficient POLE-mutated solid tumors. We found that only tumors harboring selective POLE pathogenic mutations in the DNA binding or catalytic site of the exonuclease domain presented high mutational burden with a specific single-base substitution signature, high T-cell infiltrates, and a high response rate to anti-PD-1 monotherapy. This study illustrates how specific DNA repair defects sensitize to immunotherapy. POLE proofreading deficiency represents a novel agnostic biomarker for response to PD-1 checkpoint blockade therapy., Significance: POLE proofreading deficiency leads to high tumor mutational burden with high tumor-infiltrating lymphocytes and predicts anti-PD-1 efficacy in mismatch repair-proficient tumors. Conversely, tumors harboring POLE mutations not affecting proofreading derived no benefit from PD-1 blockade. POLE proofreading deficiency is a new tissue-agnostic biomarker for cancer immunotherapy. This article is highlighted in the In This Issue feature, p. 1397., (©2022 American Association for Cancer Research.)

In the event of a criticality accident, not only the maximal doses received by the victims must be determined but it is also crucial to evaluate the doses to the different organs. With a neutron component, morphology is a key parameter in the organ dose calculation. As the simulation tools can be time consuming to proceed, especially if morphology is taken into account, for all the victims, it may be very useful to have a database of conversion coefficients that allow to obtain the organ doses from the dose measured in the dosemeter for different kinds of morphology. In this paper, we present a study performed to evaluate such conversion coefficients using voxelized anthropomorphic phantoms. These coefficients take into account two crucial parameters having an impact on the dose at the organs: the orientation of the victim in the radiation field and the morphology, that is to say the body mass index of the different victims., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)

Background: Hepatic arterial embolisation therapy (HAET) is a treatment of liver metastases of gastrointestinal neuroendocrine tumours (GI-NETs). HAET increases circulating vascular endothelial growth factor levels. Everolimus is a treatment in NETs that may have antiangiogenic activity., Methods: This phase II study was conducted in patients with predominant and progressive liver metastases from GI-NETs. Everolimus was initiated 7-30 days after HAET. The hypothesis was that everolimus after HAET would increase hepatic progression-free survival (hPFS) rate at 24 months from 35% to 50%., Results: Among the 74 patients included, 88% had small-bowel primary tumour, 43% had grade I and 57% grade II tumour, and 51% had extrahepatic metastases. Patients underwent one (n = 19), two (n = 54), or three (n = 1) HAET procedures. hPFS at 24 months was 33% (95% confidence interval [CI], 22.5-43.7); 40 (54%) patients had objective response. Median (95% CI) hPFS, PFS, and overall survival were 19 (14-23), 17 (13-22), and 51 (33-60) months. The most common grade III-IV toxicities (>5%) in patients receiving both HAET and everolimus (n = 67) were elevated liver enzymes (55%), fatigue (18%), diarrhoea (16%), anaemia (12%), hypertriglyceridaemia (7%) and mucositis (6%)., Conclusions: The primary end-point was not reached. This sequence allows high liver response with HAET, and everolimus controls the extrahepatic disease., Trial Registration: NCT01678664 (clinicaltrials.gov)., (Copyright © 2019 Elsevier Ltd. All rights reserved.)

Aims: 5-FU is the backbone of most regimens in digestive oncology. Administration of standard 5-FU leads to 15-30% of severe side effects, and lethal toxicities are regularly reported with fluoropyrimidine drugs. Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome responsible for most cases of life-threatening toxicities upon 5-FU intake, and pre-treatment checking for DPD status should help to reduce both incidence and severity of side effects through adaptive dosing strategies., Methods: We have used a simple method for rapidly establishing the DPD phenotype of patients with cancer and used it prospectively in 59 routine patients treated with 5-FU-based therapy for digestive cancers. No patient with total DPD deficiency was found but 23% of patients exhibited poor metabolizer phenotype, and one patient was phenotyped as profoundly deficient. Consequently, 5-FU doses in poor metabolizer patients were cut by an average 35% as compared with non deficient patients (2390 ± 1225 mg vs. 3653 ± 1371 mg, P < 0.003, t-test)., Results: Despite this marked reduction in 5-FU dosing, similar efficacy was achieved in the two subsets (clinical benefit: 40 vs. 43%, stable disease: 40 vs. 37%, progressive disease: 20% in both subsets, P = 0.893, Pearson's chi-square). No difference in toxicities was observed (P = 0.104, Fisher's exact test). Overall, only 3% of early severe toxicities were recorded, a value markedly lower than the 15-30% ones usually reported with 5-FU., Conclusions: This feasibility study shows how simplified DPD-based adaptive dosing of 5-FU can reduce sharply the incidence of treatment-related severe toxicities while maintaining efficacy as part of routine clinical practice in digestive oncology., (© 2015 The British Pharmacological Society.)

Background: Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment., Case Presentation: We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor., Conclusion: Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management.

Background: Gemcitabine is a mainstay in the treatment of biliary and pancreatic cancers, with limited efficacy in most settings. The gemcitabine elimination pattern is primarily driven by deamination in the liver by CDA. CDA is affected by genetic polymorphisms, leading to marked variations in activity and, subsequently, to erratic drug plasma exposures in patients administered with standard dosage. CDA deficiency has been a rising concern with gemcitabine since several studies have proven that poor metabolizer patients experience life-threatening toxicities upon drug intake. In theory, ultrarapid metabolizer (UM) patients should be conversely at risk of treatment failure, although thus far few studies have addressed this issue in digestive oncology., Patients & Methods: A pilot study was conducted on 40 pancreatic cancer patients, all treated with gemcitabine-based therapy. CDA status was primarily established on a phenotypic basis determined by measurement of residual CDA enzymatic activity in serum. Additionally, a search for c208G>A and c79A>C polymorphisms was carried out., Results: No patients carrying c208G>A polymorphisms were found, and only heterozygous c79A>C patients were observed. Eight out of the 40 patients (i.e., 20%) were identified as UM, with CDA activities over 6 U/mg. CDA activity was significantly different between progressive disease patients and patients with controlled disease (8.4 vs 3 U/mg; p < 0.001). Conversely, fewer gemcitabine-related severe toxicities were observed in UM patients., Conclusion: This pilot study strongly suggests that UM patients are nearly five-times more likely to have progressive disease than patients with normal or low CDA activities, and that beside molecular events at the tumor level, upstream deregulations affecting drug disposition should be taken into account.

PURPOSE Anticipating toxicities with gemcitabine is an ongoing story, and deregulation in cytidine deaminase (CDA) could be associated with increased risk of developing early severe toxicities on drug exposure. PATIENTS AND METHODS A simple test to evaluate CDA phenotypic status was first validated in an animal model investigating relationships between CDA activity and gemcitabine-related toxicities. Next, relevance of this test as a marker for toxicities was retrospectively tested in a first subset of 64 adult patients treated with gemcitabine alone, then it was tested in a larger group of 130 patients who received gemcitabine either alone or combined with other drugs and in 20 children. Additionally, search for the 435 T>C, 208 G>A and 79 A>C mutations on the CDA gene was performed. Results In mice, CDA deficiency impacted on gemcitabine pharmacokinetics and had subsequent lethal toxicities. In human, 12% of adult patients experienced early severe toxicities after gemcitabine administration. A significant difference in CDA activities was observed between patients with and without toxicities (1.2 +/- 0.8 U/mg v 4 +/- 2.6 U/mg; P < .01). Conversely, no genotype-to-phenotype relationships were found. Of note, the patients who displayed particularly reduced CDA activity all experienced strong toxicities. Gemcitabine was well tolerated in children, and no CDA deficiency was evidenced. CONCLUSION Our data suggest that CDA functional testing could be a simple and easy marker to discriminate adult patients at risk of developing severe toxicities with gemcitabine. Particularly, this study demonstrates that CDA deficiency, found in 7% of adult patients, is associated with a maximum risk of developing early severe toxicities with gemcitabine.

Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present two cases of capillary-leak syndrome in patients with pancreatic cancer treated with gemcitabine.

Gemcitabine is an antimetabolite drug used in the treatment of various solid tumours, including lung, pancreatic or gynaecological cancers. Innovative combinational strategies (e.g. gemcitabine+capecitabine or gemcitabine+oxaliplatin) make gemcitabine an extensively prescribed drug now. Gemcitabine is characterized by a narrow therapeutic index, and its liver elimination depends upon a key enzymatic step, driven by cytidine deaminase (CDA). CDA is prone to gene polymorphism, including the 208A>G mutation, which can result in marked enzymatic deficiency with subsequent impact on drug exposure levels and related toxicities. We have developed a simple and inexpensive method to determine phenotypically CDA status in cancer patients, as an attempt to detect those at risk upon gemcitabine intake. Conjointly to genotypic investigations, this method was used to phenotype, in a retrospective setting, a female patient displaying extremely severe, and eventually lethal, toxicities after administration of a standard gemcitabine/carboplatin protocol. Phenotypic investigation showed a marked CDA deficiency (-75%) in this patient when compared with a reference, nontoxic population. Genetic studies undertaken next to screen mutations, possibly at the origin of this deficiency, showed heterozygosity for the 79A>C single-point mutation, whereas surprisingly the canonical CDA 208A>G polymorphism was not found. Taken together, this case report demonstrates, for the first time, that CDA downregulation can lead to toxic-death in patients exposed to gemcitabine. Besides, we showed here that our cost-effective and simple phenotypic approach should enable, in the future, the detection of deficient patients at risk upon gemcitabine administration.